Ampolgen Pharmaceuticals, LLC. is in engaged in research and development of gene targeted therapies. Ampolgens current efforts focus on Sodium Phenylbutyrate (PB) and related compounds. Ampolgen was established in December of 2003, in order to engage in research, manufacturing, marketing, promotion, and sale of certain compounds which are known to effect expression of genes.
Our manufacturing facility, as well as our Research and Development unit, are located in Stafford, Texas, with Sales and Administrative office building located in neighboring West Houston,Texas.